SRPTSarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) sells gene therapy treatments for rare genetic disorders, with a focus on Duchenne muscular dystrophy and other neuromuscular diseases. The next catalyst is Nov 4, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to stabilize revenue growth and deliver on its guidance amid ongoing commercial and regulatory challenges.
- Revenue reached $1.54B in 2026, up 4.3% YoY, but free cash flow remains negative at -$1.05B TTM.
- Net margin stands at 30.9% TTM, but the company continues to grapple with high R&D and commercialization costs.
- Debt-to-equity ratio of 0.73x suggests moderate leverage, though cash flow remains a concern.
The Read
Following mixed earnings guidance that pressured the stock lower, Sarepta rallied on positive pipeline updates and strong conference engagement at the World Muscle Society Congress, reinforcing its gene therapy narrative and offsetting the earnings disappointment.
The schedule
- Wed4Nov
The earnings release will test whether SRPT can deliver strong revenue and guidance, particularly on the progress of its gene therapy pipeline and potential near-term data reads. This differs from the last print, which saw muted results due to delayed clinical updates.
- Thu10Dec
The event will test how SRPT's pricing strategy and data readouts compare to competitors, particularly in the gene therapy space. This will be a key moment to assess the company's competitive positioning and potential for market share gains.
- Mon11Jan
The conference will test SRPT's ability to present its FY2027 outlook and competitive positioning in the gene therapy space. This is a key opportunity to gauge investor sentiment and the company's strategic direction.
- Wed3Feb
This release will test the company's ability to maintain momentum from the Q3 results, particularly on the performance of its key therapies and any new data from ongoing trials. The market will be looking for signs of sustained revenue growth and improved guidance.
- Wed5May
The Q1 2027 earnings release will test the company's ability to sustain its growth trajectory, particularly on the performance of its gene therapy products and any new data from its pipeline. This will be a critical test of the company's long-term strategy and execution.
- Wed4Aug
This release will test the company's ability to deliver on its long-term growth plan, particularly on the performance of its pipeline and any new data from its trials. The market will be looking for signs of continued innovation and revenue growth.
Past
- Tue6Oct
Actual outcome: Bull · $17.85 at outcome
The stock rallied 3.1% following the World Muscle Society Congress & Pipeline Readouts, driven by positive pipeline updates and strong conference engagement that reinforced Sarepta's gene therapy narrative. The price movement aligned with the bull target, indicating market confidence in the company's long-term prospects despite mixed earnings results.
Pipeline updates at major conferences typically favor Sarepta's gene therapy narrative, potentially driving a rebound.
- Wed5Aug
Actual outcome: Bear · $17.19 at outcome
SRPT reported EPS of 3.15, matching the estimate, but guidance was lowered due to softer-than-expected demand in key markets. The stock fell as the reduced guidance signaled potential near-term revenue challenges, outweighing the neutral earnings report.
With shares pushing to $19.28 and technically overbought, expectations are elevated heading into the print.
- Mon1Jun
Actual outcome: Bull · $18.20 at outcome
